Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CLCF1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLCF1/CRLF1 Heterodimer Complex Protein HEK293 expressed, High Purity (>95%), Endotoxin Controlled, Sequence Verified. Preserves native conformational epitopes. |
View CLCF1 Products |
| Gene Delivery | CLCF1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Ideal for target validation and signaling assays. |
View CLCF1 Products |
| Benchmark Ab | Anti-CLCF1 Recombinant Antibody Recombinant positive control derived from clinical-stage/published neutralizing sequences. |
View CLCF1 Products |
| Validator | CLCF1 siRNA Set Target-specific knockdown pool for functional verification and specificity validation. |
View CLCF1 Products |
| Related Target A | CRLF1 (Cytokine Receptor-Like Factor 1) Required obligate extracellular partner that forms a functional heterodimer with CLCF1 to enable secretion and receptor binding. |
View CRLF1 Products |
| Related Target B | CNTFR (Ciliary Neurotrophic Factor Receptor) The primary cognate receptor for the CLCF1/CRLF1 complex, initiating downstream JAK/STAT signaling. |
View CNTFR Products |
| Related Target C | gp130 (IL6ST) Common signal-transducing beta-subunit shared by the IL-6 family, critical for off-target and selectivity profiling. |
View gp130 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Unstable monomeric expression & poor secretion | Co-expressed CLCF1/CRLF1 heterodimer complex from HEK293, ensuring native folding and stoichiometric stability. |
| Selectivity screening against IL-6 family homologs | Comprehensive panel of gp130-associated receptors (CNTFR, LIFR, gp130) verified by mass spectrometry and high purity (>95%). |
| Lack of standardized positive controls | Sequence-verified clinical benchmark antibodies available for binding and neutralization comparison. |
| Off-target validation in cell models | Sequence-verified CLCF1 siRNA pool and Lentiviruses for precise knock-down and over-expression studies. |
Live CLCF1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CLCF1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to targeted biologics that disrupt the CLCF1-CNTFR axis. Originally characterized as a neurotrophic factor, CLCF1 (Cardiotrophin-like cytokine factor 1) is now recognized as a critical driver of tumor progression, particularly in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). It plays a crucial role in mediating resistance to EGFR inhibitors by activating bypass JAK/STAT signaling pathways.
As first-generation therapies reach the clinic, the next wave of R&D is targeting the specific disruption of the CLCF1/CRLF1 heterodimer interface or developing bispecific therapeutic strategies targeting both CLCF1 and co-receptors like EGFR or MET to overcome drug resistance in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing mAbs | Academic Institutes, Biotech Startups | EGFR-resistant NSCLC, Myelofibrosis | Ligand-receptor blocking assays (Requires high-purity CLCF1/CRLF1 complex and CNTFR) |
| Decoy Receptors / Fusion Proteins | Oncology-focused Biotechs | Solid Tumors, Cachexia | Affinity determination and structural integrity verification (Requires sequence-verified gp130/LIFR/CNTFR panels) |
| Combination Therapies (Small Mol + Biologics) | Pharma Consortia | KRAS/EGFR Mutant Cancers | In vitro resistance modeling (Requires Lentivirus for stable cell line construction and cell-based signaling assays) |